Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure
(2025)
Journal Article
Schmid, I., O'Neill, A. F., Watanabe, K., Aerts, I., Branchereau, S., Brock, P. R., Dandapani, M., Fresneau, B., Geller, J., Hishiki, T., Ingham, D., Kraal, K., Ronghe, M., Tiao, G., Trobaugh-Lotrario, A., Rangaswami, A., Sullivan, M. J., Zsiros, J., Hiyama, E., Malogolowkin, M., & Ansari, M. (2025). Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure. EJC Paediatric Oncology, 5, Article 100235. https://doi.org/10.1016/j.ejcped.2025.100235
Malignant liver tumors affecting children and adolescents are rare. In order to adequately study liver tumors occurring in this patient population and establish a more uniform approach to therapy, the three primary liver tumor consortia, SIOPEL (main... Read More about Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure.